Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00464113 · ClinicalTrials.gov registry record · Phase 1
Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia
A Phase 1 study, sponsored by Exelixis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT00464113 is a Phase 1 study that was terminated before completion, run by Exelixis. The registered enrollment target is 49 participants.
The verdict
NCT00464113, a Phase 1 study, was terminated before completion, sponsored by Exelixis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safest dose of the BCR-ABL inhibitor XL228, how often it should be taken, and how well people with leukemia tolerate XL228.
Interventions
- DRUG XL228
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2007-05 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00464113
The ClinicalTrials.gov registry entry for NCT00464113 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XL228 is the first listed.
NCT00464113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00464113 about?
NCT00464113 is a clinical study titled "Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia". The purpose of this study is to determine the safest dose of the BCR-ABL inhibitor XL228, how often it should be taken, and how well people with leukemia tolerate XL228.
What is the current status of trial NCT00464113?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2007-05. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00464113?
The interventions under investigation include: XL228 (DRUG).
Who is sponsoring clinical trial NCT00464113?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.